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A randomised phase II trial of Epirubicin and 5-Fluorouracil versus
Cisplatinum in the palliation of advanced and recurrent malignant tumour
of the salivary glands
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Summary Sixteen patients with advanced and recurrent malignant salivary gland tumours were admitted to a
randomised trial and the response assessed. Seven patients received Epirubicin/5-Fluorouracil and none of
these patients responded. Nine patients received Cisplatinum and only one patient had a partial response. The
trial suggests that chemotherapy has no place in the treatment of advanced salivary gland malignant tumours.
Malignant salivary gland neoplasms are characterised by a
high risk of local recurrence (Budd & Groppe, 1983) and a
tendency for local invasion. Nodal metastases occur late and
40% of all patients eventually develop distant metastases
(Vermeer & Pinedo, 1979). The latter are most frequent in
the lungs, but may also occur in the bones, brain, liver, and
other viscera. These characteristics are particularly common
in adenoid cystic carcinoma. The four most common malig-
nant salivary tumours cited in a large series (Spiro & Spiro,
1989) were mucoepidermoid (34%), adenoid cystic carcinoma
(22%), adenocarcinoma (18%), and malignant mixed tumour
(13%). Local recurrence is a particular problem with malig-
nant salivary gland disease, and in one series the recurrence
rate for tumours in the parotid, submandibular, and minor
salivary glands was 39%, 60%, and 65% respectively (Spiro,
1986). Consequently, adjunctive treatment, particularly with
irradiation, is widely practiced (Shidnia et al., 1980). Even so
locoregional recurrence remains a persistent problem.
Malignant salivary gland tumours are relatively uncom-
mon forming only 5% of all head and neck malignancies
(Rentschler et al., 1977) and thus the experience in any one
centre of treating these diseases is limited.
There is little information on the use of chemotherapy for
advanced and recurrent malignant tumours as only small
studies have been performed on a variety of agents. The most
effective drugs are thought to be doxorubicin hydrochloride
(dox), Hexamethylmelamine, Cisplatinum, and 5-Fluor-
ouracil (Budd & Groppe, 1983; Vermeer & Pinedo, 1979;
Rentschler et al., 1977; Johnson et al., 1964; Alberts et al..
1981; Skibbia et al., 1981; Creagan et al., 1983; Richards &
Chambers, 1973; Moore et al., 1968). Dox and 5-
Fluorouracil appear to be synergistic.
In the present study the efficacy of the less toxic dox
analogue Epirubicin in combination with 5-Fluorouracil is
compared with Cisplatinum in the palliation of advanced and
recurrent malignant salivary tumours.
Patients and methods
A Phase II crossover study is reported (Herson, 1984). All
patients had recurrent, advanced, malignant tumours of the
salivary glands and were unsuitable for surgery or radio-
therapy. Patients were randomised by drawing cards from a
bag to Cisplatinum only or Epirubicin and 5-Fluorouracil
(5FU). If no response occurred after two courses or if the
disease progressed the patient was crossed over to the other
regimen.
Criteria of response, duration of response, and toxicity
were as laid down by Miller et al. (1981), and patients were
followed up fortnightly.
The number of patients needed for the trial was calculated
using Gehan's rule (1961). Fourteen patients were to be
admitted initially, a number sufficient to detect a 20% res-
ponse with a power of 95%. If no response had occurred the
trial would have been terminated. In the event 16 patients
were admitted to the trial (Tables I and II).
Each tumour was carefully assessed and classified by site
and stage (UICC, 1987). The assessment included measuring
the perpendicular diameter using calipers; palpation for local
neck disease; pharyngeal endoscopy and appropriate radio-
logy. The patients's general condition was classified by the
Karnofsky scale (Beahrs et al., 1988) and all patients under-
went a complete general physical examination. All patients
were seen by a Consultant Physician, as part of their initial
assessment and who also advised on management during the
administration of chemotherapy.
Investigations included a full blood count and white
differential count, serum urea and electrolytes, 24 h creatinine
clearance, liver function tests, chest radiography, electrocar-
diography and a pure tone audiogram.
Specific exclusion criteria included those patients with his-
tology showing squamous cell carcinoma, undifferentiated
carcinoma, or lymphoma; patients with impaired renal func-
tion characterised by a creatinine clearance of less than 50 ml
per min and patients with impaired liver function or
significant cardiac disease.
The proposed administration of chemotherapy was dis-
cussed with each patient and their relatives by explaining its
intended purpose and the possible side effects of the treat-
ment. It was emphasised that the patient had every right to
refuse admission to the trial and withdraw at any stage.
The trial was passed by the Royal Liverpool University
Hospital Ethics Committee.
Dosage and administration
In order to be treated a patient had to satisfy the following
criteria:
(1) A Karnofsky performance status greater than 50.
(2) The patient's white blood count was greater than
4000 mm-3 and platelet count greater than
100,000 mm-3.
(3) Creatinine clearance greater than 50 ml minl. The
group to be given Cisplatinum were prehydrated with 2
litres of normal saline administered intravenously over
12 h and received one dose of 12.5 g of Mannitol.
The dose ofcisplatinum administered was modified accord-
ing to renal function as follows:
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Table I Host factors
Epirubicin + 5-FU Cisplatinum
Number 7 9
Age in years (Mean) 53 61
Sex ratio (M:F) 2.5:1 3.5:1
Karnofsky (Median) 80 80
Table II Tumour factors
Epirubicin + 5-FU Cisplatinum
Histology
Adenocarcinoma 3 3
Malignant mixed 0 1
Adenoid cystic carcinoma 3 2
Mucoepidermoid carcinoma 1 2
Acinic cell tumour 0 1
Site
Oropharynx 0 1
Oral cavity 0 3












and given over 6-8 h as an intravenous infusion. Post hydra-
tion was with 11 of normal saline over 2 h.
The other group received Epirubicin (75 mg m-2) given
over 6-8 h followed by 5-Fluorouracil (100mgm2) given
over 24 h as an intravenous infusion.
The total cumulative doses of Epirubicin did not exceed
700 mg m2 and of Cisplatinum, 600 mg m2.
Analysis ofthe data
Survival curves were constructed using the method of Kaplan
and Meier (1985) and were compared for the two groups
using the log rank test (Peto et al., 1977).
Categories of response for the two groups were compared
by Fisher's test of exact probability.
Results
There was no response to treatment in the Epirubicin and
5-Fluorouracil group and only one partial response in those
receiving Cisplatinum.
The median survival was 243 days for the Epirubicin/5-FU
group and 450 days for the Cisplatinum group. The
difference in survival was not significant (X2 = 0.3, d.f. = 1).
The results are displayed in Table III.
Discussion
Studies concerning malignant salivary gland tumours are rare
and have concentrated on small numbers of patients exposed
to a variety of chemetherapeutic agents including Methotrex-
ate, 5-FU, dox, Hydroxyurea, C.C.N.U. (1-(2-chlorethyl)-3-
cyclohexyl-l-nitrosourea), Vincristine, Cisplatinum, Cyclo-
phosphamide, Hexamethylmelamine, Bleomycin, and Chlor-
ambucil (Budd & Groppe, 1983; Vermeer & Pinedo, 1979;
Table III Treatment and outcome
Epirubicin + 5-FU Cisplatinum
Median number of courses
(Range) 2 (1-5) 2 (0-6)
Response
Progressive disease 5 5
Stable disease 2 3
Partial response 0 1
Complete response 0 0
(Fisher's exact test P = 0.56)
Median survival (days) 243 450
(X2 = 0.3, df= 1, N.S.)
Rentschler et al., 1977; Johnson et al., 1964; Alberts et al.,
1981; Skibba et al., 1981; Creagan et al., 1983; Richards &
Chambers, 1973; Moore et al., 1968). Some of these studies
are case reports and some are trials. The two large
chemotherapy series (Rentschler et al., 1977; Tannock &
Sutherland, 1980), consist of 36 and 17 patients respectively.
Rentschler (1977) reports six patients each giving a partial
response with a single agent (dox and Hexamethylamine) and
two partial responses with combination chemotherapy from
36 patients treated. The median duration of survival from
initiation of chemotherapy was 6 months. Alberts et al.
(1981) and Creagan et al. (1983) in two separate studies using
dox, Cyclophosphamide and Cisplatinum both achieved a
complete response in two patients, the median duration of
this response being 5 months. They also achieved a partial
response in three and six patients respectively with a median
duration of 6 months in both groups. Other studies (Budd &
Groppe, 1983; Vermeer & Pinedo, 1979; Alberts et al., 1981;
Tannock & Sutherland, 1980) reported partial responses with
median durations of 5 weeks, 5 months, and 12 months.
Combination regimens, such as Cylcophosphamide/dox/
Cisplatinum (Alberts et al., 1981; Creagan et al., 1983) and
Cyclophosphamide/dox/Vincristine (Skibba et al., 1981) show
a very high response rate with a median duration ranging
from 1 to 7 months.
In the present study there was no response to Epirubicin/5-
FU and the median survival was 243 days. There was one
partial response in the Cisplatinum group and the median
survival was 450 days. The difference was not significant.
Conclusions
(1) The optimistic view summarised in the Introduction is
typical and biased - because only the good results tend
to be reported.
(2) Any difference in survival is difficult to analyse because
of the well known unpredictable long term behaviour of
salivary carcinoma and in particular adenoid cystic car-
cinoma. Therefore, for all these tumours, response is
probably a better criterion than survival unlike
squamous cell carcinoma where the converse is true.
Furthermore, chemotherapeutic trials which fail to con-
sider the effect of varying histology of malignant
salivary gland tumours on response and survival should
no longer be considered acceptable.
(3) In this study both chemotherapeutic regimens produced
equally disappointing results.
(4) This trial suggests that chemotherapy is unhelpful in the
treatment of end-stage salivary malignancy.
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